Skip to main content

Advertisement

SpringerLink
Log in

Metastatic colorectal cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Despite advances in screening procedures and the use of adjuvant therapy, approximately 50% of patients with colorectal cancer eventually will develop metastatic disease. Long-term disease-free survival can be achieved in 25% to 40% of selected patients who undergo resection of liver or lung metastases. For all other patients, treatment is palliative. For decades, 5-fluorouracil was the only available drug for colorectal cancer; hence, numerous trials were performed that used various administration schedules and modulating agents to improve therapeutic efficacy. The addition of leucovorin to 5-FU improves response but not survival. Infusion schedules alter the toxicity profile but have a negligible impact on survival. Irinotecan was the first new drug to demonstrate activity in colorectal cancer. It was used initially in the second-line setting, where it was shown to improve quality of life and survival over best supportive care or infusional 5-FU. Recently, irinotecan has been incorporated into the front-line treatment of metastatic colorectal cancer in combination with 5-FU and leucovorin; this combination improves survival by approximately 3 months. Careful patient selection and adherence to strict dose adjustments are essential to prevent significant toxicity when patients are treated on this regimen. The oral fluoropyrimidine capecitabine recently has been approved for the front-line treatment of patients with colorectal cancer who are not appropriate candidates for combination therapy. Oxaliplatin, a novel DACH (diaminocyclohexane) platinum with definite activity in colorectal cancer, is approved for this disease in Europe and is undergoing phase III clinical trials in the United States. Other drugs with potential activity in colorectal cancer include raltitrexed, pemetrexed disodium, and the epothilone analog BMS-247550 (Bristol-Myers Squibb, New York, NY). Novel cytostatics with promising activity in colorectal cancer are being evaluated in clinical trials, including epidermal growth factor receptor inhibitors, such as IMC-C225 (Imclone Systems, New York, NY) and ZD1839 (AstraZeneca, London, UK), angiogenesis inhibitors such as bevacizumab and SU5416 (Sugen, San Francisco, CA), and vaccines such as CEAVac (Titan Pharmaceuticals, San Francisco, CA). For those patients whose disease is localized to the liver, there also is an emerging role for local therapies, including cryosurgery, radiofrequency ablation, and hepatic artery infusional chemotherapy, and resection. The emergence of these new drugs and new interventional modalities has allowed physicians who treat colorectal cancer to move beyond 5-FU.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics 2001. CA Cancer J Clin 2001, 51:15–36.

    Article  PubMed  CAS  Google Scholar 

  2. Kroser JA, Bachwich DR, Lichtenstein GR: Risk factors for the development of colorectal carcinoma and their modification. Hematol Oncol Clin North Am 1997, 11:547–577.

    Article  PubMed  CAS  Google Scholar 

  3. Kindler HL, Schilsky RL: Colorectal cancer. In In Oncologic Therapies, edn. 2. Edited by: Vokes EE, Golomb HM. Berlin, Springer-Verlag, in press.

  4. Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and metaanalysis. Colorectal Cancer Collaborative Group. BMJ 2000, 321:531–535.

    Article  PubMed  CAS  Google Scholar 

  5. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10:896–903.

    Google Scholar 

  6. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16:301–308.

    Google Scholar 

  7. Leichman C, Fleming T, Muggia F, et al.: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995, 13:1303–1311.

    PubMed  CAS  Google Scholar 

  8. Shimada Y, Yoshino M, Wakui A, et al.: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993, 11:909–913.

    PubMed  CAS  Google Scholar 

  9. Rougier P, Bugat R, Douillard J, et al.: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997, 15:251–260.

    PubMed  CAS  Google Scholar 

  10. Pitot HC, Wender DB, O’Connell MJ, et al.: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997, 15:2910–2919.

    PubMed  CAS  Google Scholar 

  11. Conti JA, Kemeny NE, Saltz LB, et al.: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14:709–715.

    PubMed  CAS  Google Scholar 

  12. Cunningham D, Pyrhonen S, James R, et al.: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413.

    Article  PubMed  CAS  Google Scholar 

  13. Rougier P, VanCutsem E, Bajetta E, et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407–1412.

    Article  PubMed  CAS  Google Scholar 

  14. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New Engl J Med 2000, 343:905–914. The randomized phase III trial that established the superiority of the three-drug regimen of 5-FU, leucovorin, and irinotecan in terms of response rate, survival, and progression-free survival.

    Article  PubMed  CAS  Google Scholar 

  15. Douillard J, Cunningham D, Roth A, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000, 355:1041–1047.

    Article  PubMed  CAS  Google Scholar 

  16. Sargent DJ, Niedzwiecki D, O’Connell MJ, Schilsky RL: Recommendations for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. New Engl J Med 2001, 344:1. An important letter to the editor that alerts clinicians to the potential toxicities of combination therapy with 5-FU, leucovorin, and irinotecan.

    Google Scholar 

  17. vanCutsem E, Findlay M, Osterwalder B, et al.: Capecitabine, an oral fluoropyrimidine with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000, 18:1337–1345.

    PubMed  Google Scholar 

  18. Hoff P, Ansari R, Batist G, et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19:2282–2292.

    PubMed  CAS  Google Scholar 

  19. Sharma S, Saltz LB: Oral chemotherapeutic agents for colorectal cancer. Oncologist 2000, 5:99–107. Reviews the economic considerations for the development of oral regimens for colorectal cancer.

    Article  PubMed  CAS  Google Scholar 

  20. Cromheecke M, de Jong KP, Hoekstra HJ: Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol 1999, 25:451–463. An excellent review of treatment strategies for colorectal cancer metastatic to the liver.

    Article  PubMed  CAS  Google Scholar 

  21. Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938–946.

    PubMed  CAS  Google Scholar 

  22. Bilchik AJ, Wood TF, Allegra D, et al.: Cryosurgical ablation and radiofrequency ablation for unresectable hepatic neoplasms: a proposed algorithm. Arch Surg 2000, 135:657–664.

    Article  PubMed  CAS  Google Scholar 

  23. Girard P, Ducreeux M, Baldeyrou P, et al.: Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol 1996, 14:2047–2053.

    PubMed  CAS  Google Scholar 

  24. Tebbutt NC, Norman A, Livingston S, et al.: Chemotherapy as initial treatment in patients with unresected primary colorectal cancer and synchronous metastases. Proc Am Soc Clin Oncol 2001, 20:524.

    Google Scholar 

  25. Meta-analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996, 88:252–258.

    Article  Google Scholar 

  26. Haller DG: Waiting for the definitive trial of hepatic arterial chemotherapy for colorectal cancer. J Clin Oncol 2000, 18:239–242. A thoughtful discussion of the problems and promise of trials using hepatic arterial infusion.

    PubMed  CAS  Google Scholar 

  27. Lorenz M, Muller HH, for the German Cooperative Group on Liver Metastases: Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000, 18:243–254.

    PubMed  CAS  Google Scholar 

  28. Kemeny N, Huang Y, Cohen A, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039.

    Article  PubMed  CAS  Google Scholar 

  29. Becouarn Y, Yehou M, Ducreux M, et al.: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer. J Clin Oncol 1998, 16:2739–2744.

    PubMed  CAS  Google Scholar 

  30. Machover D, Diaz-Rubio E, deGramont A, et al.: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7:95–98.

    PubMed  CAS  Google Scholar 

  31. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938–2947. An important trial that demonstrates that the addition of oxaliplatin to 5-FU and leucovorin significantly improves response rates, but not survival.

    PubMed  Google Scholar 

  32. Zalcberg JR, Cunningham D, vanCutsem Cutsem E, et al.: ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex colorectal study group. J Clin Oncol 1996, 14:716–721.

    PubMed  CAS  Google Scholar 

  33. Pazdur R, Vincent M: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 1997, 16:801.

    Google Scholar 

  34. Blanke CD, Kasimis B, Schein P, et al.: Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 1997, 15:915–920.

    PubMed  CAS  Google Scholar 

  35. Punt CJ, Keizer HJ, Douma J, et al.: Multicenter randomized trial of 5-Flourouracil (5-FU) and leucovorin (LV) with or without trimetrexate (TMTX) as first-line treatment in patients (pts) with advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1999, 18:1006.

    Google Scholar 

  36. John W, Picus J, Blanke CD, et al.: Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000, 88:1807–1813.

    Article  PubMed  CAS  Google Scholar 

  37. Bollag DM, McQueney PA, Zhu J, et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995, 55:2325–2333.

    PubMed  CAS  Google Scholar 

  38. Pazdur R, Lassere Y, Rhodes V, et al.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994, 12:2296–2300.

    PubMed  CAS  Google Scholar 

  39. Kindler HL, Schilsky RL: Eniluracil. Expert Opin Investig Drugs 2000, 9:1635–1649.

    Article  PubMed  CAS  Google Scholar 

  40. Ohtsu A, Baba H, Sakata Y, et al.: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000, 83:141–145.

    Article  PubMed  CAS  Google Scholar 

  41. Saltz L, Rubin M, Hochster H, et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001, 20:3a. This important trial demonstrates the activity of the combination of a monoclonal antibody to the epidermal growth factor receptor plus irinotecan in patients refractory to irinotecan.

    Google Scholar 

  42. Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053–2063.

    PubMed  CAS  Google Scholar 

  43. Bergsland E, Hurwitz H, Fehrenbacher L, et al.: A randomized phase II trial comparing rhuMAb VEGF (Recombinant Humanized monoclonal antibody to vascular endothelial growth factor) plus 5-FU/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000, 19:242a.

    Google Scholar 

  44. Eng C, Kindler HL, Stadler WM, et al.: SU5416 in advanced colorectal cancer (CRC): a University of Chicago phase II consortium study. Proc Am Soc Clin Oncol 2001, 20:116b.

    Google Scholar 

  45. Hwang J, Sinicrope F, Safran H, et al.: A Phase II Trial of Irinotecan and Trastuzumab (Herceptin) in Patients (Pts) Overexpressing HER-2/neu in Metastatic Colorectal Cancer (CRC). Proc Am Soc Clin Oncol 2001, 20:142a.

    Google Scholar 

  46. Foon KA, John WJ, Chakraborty M, et al.: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999, 17:2889–2895.

    PubMed  CAS  Google Scholar 

  47. Twelves C, Harper P, Cutsem EV, et al.: A phase III trial (SO14796) of Xeloda (Capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999, 18:1010a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology, University of Chicago Medical Center, 5841 S. Maryland Avenue, MC 2115, 60637, Chicago, IL, USA

    Hedy Lee Kindler MD & Keith L. Shulman MD

Authors
  1. Hedy Lee Kindler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keith L. Shulman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kindler, H.L., Shulman, K.L. Metastatic colorectal cancer. Curr. Treat. Options in Oncol. 2, 459–471 (2001). https://doi.org/10.1007/s11864-001-0068-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-001-0068-7

Keywords

Search

Navigation